多发性骨髓瘤研究进展和治疗选择研讨.ppt

New Developments and Treatment Options for Multiple Myeloma;多发性骨髓瘤研究进展和治疗选择;Outline;内容大纲;Diagnostic Criteria;诊断标准;Arriving at the Diagnosis;确诊条件;Problems with This Method;这项标准存在的问题;MGUS;MGUS;Asymptomatic Multiple Myeloma;无症状多发性骨髓瘤;Symptomatic Multiple Myeloma;有症状多发性骨髓瘤;Durie-Salmon Staging System;Durie-Salmon 分期系统;International Staging System;国际分期系统（ISS）;1;1;Cytogenetic Factors : Del 13;细胞遗传学指标 : 13号染色体缺失;Bortezomib and Del 13;万珂 与 13号染色体缺失;Conclusions;结 论;Outline;内容大纲;Thalidomide + Dexamethasone;沙立度胺 + 地塞米松;DVd vs. VAd as Initial Therapy;DVd vs. VAd 作为初始治疗;Should We Push Harder for a CR ?;我们是否应更努力去取得 CR ?; Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma;Lenalidomide 联合地塞米松 (Rev/Dex) 治疗新诊断的骨髓瘤;Study Design;研究设计;Responses;疗效;Toxicities;毒性反应;PAD Regimen; PAD方案;Outcomes Data;疗效结果;Toxicities;毒性反应; Reduced Dose PAD Combination Therapy (PS-341/ Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple MyelomaRakesh Popat, Heather E. Oakervee, Nicola Curry, Nicola Foot, Curly Morris, Mary Drake, Samir Agrawal, Patricia Smith, David Schenkein, Dixie-Lee Esseltine, Jamie D. Cavenagh Haematology, St. Bartholomews Hospital, London, United Kingdom; Haematology, Belfast City Hospital, Belfast, United Kingdom; Millennium Pharmaceuticals, Cambridge, MA, USA;减量PAD联合方案（PS-341/硼替佐米, 阿霉素和地塞米松）治疗初治的多发性骨髓瘤Rakesh Popat, Heather E. Oakervee, Nicola Curry, Nicola Foot, Curly Morris, Mary Drake, Samir Agrawal, Patricia Smith, David Schenkein, Dixie-Lee Esseltine, Jamie D. Cavenagh Haematology, St. Bartholomews Hospital, London, United Kingdom; Haematology, Belfast City Hospital, Belfast, United Kingdom; Millennium Pharmaceuticals, Cambridge, MA, USA;Toxicities;毒性反应;Responses;疗效;Conclusions;结论;Outline;内容大纲; A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma (MM) Patients;万珂联合美法兰、强的松 (V-MP)用于老年初治的多发性骨髓瘤患者 (MM)